ClinicalTrials.gg
CompletedNCT00837356Updated Feb 10, 2017

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

A Phase 1 interventional study of Advate® and turoctocog alfa in Congenital Bleeding Disorder and Haemophilia A, sponsored by Novo Nordisk A/S. Completed at 7 sites in 5 countries. Open to male participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-02-10.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
12 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
13th of 21
23 · median 50
Started
2009
with 3 others
Phase 1
3 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
1 of 21
Novo Nordisk A/S

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 13th largest by enrollment, is one of 4 that started in 2009, is one of 3 in phase 1, and was the 6th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

This trial is conducted in Europe and Asia. The aim of this clinical trial is to compare two recombinant factor VIII drugs, turoctocog alfa (recombinant factor VIII (N8)) with Advate®, in haemophilia A subjects, investigating the action and safety of the drugs.

03

Conditions studied

  • Congenital Bleeding Disorder
  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe haemophilia A (FVIII level less than or equal to 1%)
  • Treatment history of more than 150 exposure days with recombinant or plasma-derived FVIII replacement products
  • or negative, or if positive the patient is on a stable antiviral regimen at the time of the enrolment in the trial

Exclusion criteria

Exclusion Criteria:

  • Presence of any bleeding disorder in addition to haemophilia A
  • Inhibitor titre greater than or equal to 0.6 Bethesda Units (BU) at screening and past history of inhibitor
  • Abnormal renal function tests
  • Known to Advate®
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Advate®/turoctocog alfa

    Drug: Advate® · Drug: turoctocog alfa

Interventions

  • Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session

  • After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session

    Also known as: recombinant FVIII, N8

06

What researchers measure

Primary outcomes

  1. Recovery of FVIII 30 min after administration, half-life, AUC, and clearance

    Time frame: at 30 days

Secondary outcomes

  1. Inhibitor development

    Time frame: at 30 days

07

Study locations

7 sites
  • Novo Nordisk Investigational Site
    Berlin, 10249, Germany
  • Novo Nordisk Investigational Site
    Hannover, 30625, Germany
  • Novo Nordisk Investigational Site
    Tel-Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Firenze, 50134, Italy
  • Novo Nordisk Investigational Site
    Milano, 20124, Italy
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Zürich, 8091, Switzerland
08

References and documents

Publications

  • Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011 Nov;17(6):854-9. doi: 10.1111/j.1365-2516.2011.02495.x. Epub 2011 Mar 28. PubMed 21443634 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2009
First posted
Feb 5, 2009
Start
Mar 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Feb 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00837356
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 5, 2009
Start date
Mar 2009
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Feb 10, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antihemophilic factor, human recombinant

Start the discussion